http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#Head http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#assertion http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#provenance http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#pubinfo http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#assertion http://purl.obolibrary.org/obo/DOID_12700 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_12700 http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB01200 http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association http://www.w3.org/2000/01/rdf-schema#label bromocriptine mesylate tablets usp are indicated for the treatment of dysfunctions associated with hyperprolactinemia amenorrhea galactorrhea infertility or hypogonadism prolactin secreting adenomas reduction tumor size bromocriptine mesylate tablets usp are indicated in the treatment of acromegaly bromocriptine mesylate tablets usp therapy alone or as adjunctive therapy with pituitary irradiation or surgery reduces serum growth hormone by 5 or more in approximately one half of patients treated although not usually to normal levels since the effects of external pituitary radiation may not become maximal for several years adjunctive therapy with bromocriptine mesylate tablets usp offers potential benefit before the effects of irradiation are manifested bromocriptine mesylate tablets usp are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic parkinson s disease as adjunctive treatment to levodopa alone or with a peripheral decarboxylase inhibitor bromocriptine mesylate tablets usp therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa those who are beginning to deteriorate develop tolerance to levodopa therapy and those who are experiencing end of dose failure on levodopa therapy bromocriptine mesylate tablets usp therapy may permit a reduction of the maintenance dose of levodopa and thus may ameliorate the occurrence and or severity of adverse reactions associated with long term levodopa therapy such as abnormal involuntary movements e g dyskinesias and the marked swings in motor function on off phenomenon continued efficacy of bromocriptine mesylate tablets usp therapy during treatment of more than two years has not been established data are insufficient to evaluate potential benefit from treating newly diagnosed parkinson s disease with bromocriptine mesylate tablets usp studies have shown however significantly more adverse reactions notably nausea hallucinations confusion and hypotension in bromocriptine mesylate tablets usp treated patients than in levodopa carbidopa treated patients patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets usp therapy http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB01200 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#provenance http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#pubinfo http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig http://purl.org/nanopub/x/hasSignature bzsE91bAxZtKLFVBo/2OE375nP1vuZEesqcoYadRbGnw8rnRpem8ZYluEHTdo892vmWldZPtsUTeR+uipGFDZI48JI6EehI79vuoDYJJeqvQ5PnRv25K63Ty6EtXQ453MD4P2gb90w75HW6NF4xw/mtsjMp3+s4ZleIQWePzEEw= http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo http://purl.org/dc/terms/created 2021-07-03T13:13:12.279+02:00 http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAgZK738W6DoWVDDJukH-3uYN5f5iEjtGspI-JD4vwEMo https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs